CJC-1295 (no DAC) Guía & Tabla de Dosis

What is CJC-1295 (no DAC)?

CJC-1295 (no DAC) — also called Modified GRF 1-29, or simply Mod GRF 1-29 — is a synthetic peptide built to closely mimic a hormone your body already makes: growth hormone-releasing hormone (GHRH). GHRH is the natural signal your hypothalamus (a small region in your brain) sends to your pituitary gland, telling it to release growth hormone (GH) into the bloodstream.

The "no DAC" part of the name is important. DAC stands for Drug Affinity Complex — a molecular attachment used in the related compound CJC-1295 with DAC that makes it linger in the body for days. Without DAC, this peptide is cleared much faster, producing a sharper, shorter spike in GH rather than a prolonged elevation. Think of it like a quick burst of signal rather than a slow-release notification.

Researchers and scientists use CJC-1295 (no DAC) as a research-use-only tool to study the body's GH-releasing system. It is not approved for human therapeutic use, and nothing here should be read as medical advice.

How CJC-1295 (no DAC) Works

Here's a simple way to picture it. Your pituitary gland is like a factory that makes growth hormone. The factory only runs when it gets the right delivery order — and that order is GHRH. Natural GHRH, however, is fragile: enzymes in the blood chew it up within a few minutes, so the delivery order barely arrives before it's destroyed.

CJC-1295 (no DAC) is an engineered version of that delivery order. Scientists swapped out four of the original amino acids (the building blocks) in natural GHRH's 1-29 sequence to make it more resistant to those enzyme attacks. The result is a peptide that survives long enough to reach the pituitary, bind to the GHRH receptor, and trigger a pulse of GH release — but is still cleared from the body within roughly 30 minutes to an hour, preserving something close to the natural pulsatile rhythm of GH secretion.

This pulsatile pattern is considered important in research because normal GH in the body is released in bursts, not as a constant flood. Mod GRF 1-29 is therefore studied as a way to stimulate GH in a more physiologically relevant pattern compared to longer-acting analogs.

What the Research Shows

Because no numbered source abstracts were provided for this page, we cannot cite specific study findings here. What the broader scientific literature explores includes how GHRH analogs interact with pituitary receptors, how modified peptide sequences affect enzymatic stability, and how pulsatile versus continuous GH stimulation differs in animal and cell-based models. Researchers interested in the primary literature should search peer-reviewed databases for studies on "Mod GRF 1-29," "GHRH analogs," and "CJC-1295 without DAC" for the most current findings.

What CJC-1295 (no DAC) Is Being Studied For

As a research peptide, CJC-1295 (no DAC) is primarily studied in the following areas:

• Growth hormone secretion mechanics — understanding how the pituitary responds to short GHRH pulses versus prolonged stimulation.
• Receptor binding studies — investigating how structural modifications to GHRH affect affinity and activation of the GHRH receptor.
• Metabolic research — exploring connections between GH pulsatility and metabolic markers in preclinical models.
• Combination peptide research — Mod GRF 1-29 is frequently studied alongside GHRPs (Growth Hormone Releasing Peptides) like GHRP-2 or Ipamorelin, which work through a different receptor (the ghrelin receptor). Used together in research settings, they are thought to produce a synergistic GH pulse by activating two separate pathways simultaneously.
• Aging biology — some researchers investigate GHRH analogs in the context of age-related decline in GH secretion.

It is worth repeating: all of this is preclinical and exploratory research. CJC-1295 (no DAC) has not been approved as a drug or therapy by any major regulatory body.

How CJC-1295 (no DAC) Is Dosed in Research

Dosing in research settings varies depending on the study design, the model being used, and what endpoint is being measured. Rather than list specific amounts here — which could be misread as prescriptive advice — we've compiled the reference ranges reported across preclinical and early human-model studies in the dosage chart on this page. If you're working through a protocol and need to convert quantities or scale across concentrations, the calculator tool on this site can help. Always remember: these figures are reference points for research purposes only.

Mixing and Storing CJC-1295 (no DAC)

CJC-1295 (no DAC) is typically supplied as a lyophilized powder — a dry, freeze-dried cake in a sealed vial. Before it can be used in research, it needs to be reconstituted, meaning dissolved into a liquid. The most common diluent used in research settings is bacteriostatic water (sterile water containing a small amount of benzyl alcohol, which helps prevent bacterial growth in the vial). Some researchers use sterile water for single-use preparations instead.

To reconstitute, the liquid is drawn into a syringe and injected slowly down the side of the vial — not squirted directly onto the powder, which can damage the peptide. Swirl gently; never shake. Once dissolved, the solution should be clear and colorless. Any cloudiness or particulates are a sign something has gone wrong.

For storage: unreconstituted powder is generally kept in a freezer (around -20°C / -4°F) and protected from light. Once reconstituted, vials are typically stored in a refrigerator (2–8°C / 36–46°F) and used within a few weeks, though exact stability windows depend on the specific formulation and conditions. Always follow the supplier's guidance and standard laboratory storage protocols.